Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 NET 1 Head & Neck 1 Gastrointestinal 1 Endocrine 1 CNS 1

Conditions

Neoplasms 21 Neoplasm Metastasis 10 Neoplasms, Unknown Primary 1 Carcinoma, Squamous Cell 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Oxaliplatin 14 Gemcitabine 13 Fluorouracil 11 Leucovorin 9 Capecitabine 9 pembrolizumab 7 Docetaxel 7 Irinotecan 6 Paclitaxel 5 zolbetuximab 4 regorafenib 4 Trastuzumab 4 Radiotherapy 4 Pemetrexed 4 S 1 (combination) 3 Ramucirumab 3 Nivolumab 3 Drug Therapy 3 Cisplatin 3 Bevacizumab 3 vandetanib 2 tislelizumab 2 sargramostim 2 lenvatinib 2 icotinib 2 camrelizumab 2 bemarituzumab 2 apatinib 2 Phlebotomy 2 Esophagectomy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × atezolizumab × Tumor-Agnostic × Clear all

NCT05968326 2026-05-11

IMCODE003

Genentech, Inc.

Phase 2 Recruiting

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡